⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 28, 2026Journal of Clinical Oncology

Genomic instability score (GIS) and real-world outcomes in patients (pts) with advanced ovarian cancer (aOC) using a U.S. health database.

Rebecca C. Arend Nicole Niehoff Jean Hurteau Nistha Shah Amanda Golembesky Jonathan Lim Matthias Hünger Jaya Paranilam Elizabeth M. Swisher

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to associate genomic instability score cutoffs with real-world outcomes in advanced ovarian cancer patients receiving PARPi treatment.
Retrospective evaluation using the Flatiron Health database from January 2017 to March 2025.
Included patients with advanced ovarian cancer treated with first-line platinum-based chemotherapy followed by PARPi maintenance.
Kaplan Meier and Cox regression analyses were used to evaluate the association of GIS cutoffs with progression-free survival and time to next treatment.
Higher genomic instability scores correlating with increased median progression-free survival and time to next treatment.
Cutoff GIS ≥42 showed the greatest improvement, with unadjusted HRs indicating significant clinical benefit at various thresholds.
Only 44% of patients had progression data, limiting adjusted analyses for progression-free survival.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Evaluates genomic instability score and its impact on outcomes in advanced ovarian cancer, suggesting critical implications for treatment decisions.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Arend et al. (2026) studied this question.

synapsesocial.com/papers/6a1a812b0307b785094331b5 https://doi.org/10.1200/jco.2026.44.16_suppl.e17565

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy prediction for progression-free survival (PFS) and overall survival (OS) by genomic instability score (GIS) cutoffs in patients (pts) with advanced ovarian cancer (aOC): Post hoc results from the phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial.Late-Phase Clinical Trial · 2026
21213 Survival according to the type of genetic anomaly2024
3Understanding Genomic Instability Score in Platinum-Treated Advanced Pancreatic Ductal AdenocarcinomaOriginal Research · 2026
4Leveraging genomic instability scores (GIS) to investigate BRCA variants of unknown significance (VUS) in ovarian cancer: An analysis of 14,513 patients in the Myriad Collaborative Research Registry (MCRR).2024
5A US real-world study of second-line outcomes in advanced ovarian cancer by first-line PARP inhibitor maintenance exposure.Cohort Study · 2026

Survival differences in advanced gynecological cancers after the development of immune checkpoint inhibitors and targeted therapy: United States SEER-based population study.2026
Assessing disparities in real-world overall survival (rwOS) among sociodemographic groups in advanced ovarian cancer (aOC): The impact of biomarker testing and first-line (1L) maintenance therapies (mtx).2025
Predictors of real-world progression-free survival (rwPFS) in patients (pts) with epithelial ovarian cancer (EOC) treated with first-line maintenance (1LM) niraparib (nir): Post hoc analysis of the 1NSPIRE chart review study.2026
Methylphenidate for Hematologic Cancer–Related Fatigue: A Randomized Clinical TrialJournal of Clinical Oncology · 2026
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.4Journal of Clinical Oncology · 2026

More from Journal of Clinical Oncology

More from University of Alabama at Birmingham

More from Fred Hutch Cancer Center

More from Providence College

More from University of Alabama at Birmingham Hospital